Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vosaroxin - Denovo Biopharma/Sumitomo Pharma

Next Previous
X
Search
Drug Profile

Vosaroxin - Denovo Biopharma/Sumitomo Pharma

Alternative Names: AG-7352; AG-7352 hydrochloride; DB 106; QINPREZO; SNS-595; SPC-595; Voreloxin

Latest Information Update: 12 Feb 2025

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dainippon Sumitomo Pharma
  • Developer Cardiff University; Sunesis Pharmaceuticals; University of Texas M. D. Anderson Cancer Center; Vanderbilt-Ingram Cancer Center; Viracta Therapeutics; Washington University School of Medicine; Weill Cornell Medical College
  • Class Antineoplastics; Carboxylic acids; Naphthyridines; Pyrrolidines; Quinolones; Small molecules; Thiazoles
  • Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia
  • Phase II/III Myelodysplastic syndromes; Precursor B-cell lymphoblastic leukaemia-lymphoma
  • No development reported Glioblastoma
  • Discontinued Non-small cell lung cancer; Ovarian cancer; Small cell lung cancer

Most Recent Events

  • 12 Feb 2025 Efficacy results from the phase II/III trial in Acute myeloid leukaemia presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)
  • 28 Jan 2025 No recent reports of development identified for phase-I development in Myelodysplastic-syndromes(Combination therapy, Second-line therapy or greater) in USA (IV)
  • 29 Apr 2024 Sunesis Pharmaceuticals completed phase-I trials in Myelodysplastic syndromes (Combination therapy, Second-line therapy or greater) in USA (IV) (NCT01913951)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top